[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"staging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:staging":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,74,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100470562","thereapeutic-recommendantion-for-children-with-a-hodgkin-lymphoma-100470562",false,"NCT05407480","Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma","Therapeutic Recommendations for Children Registered in the RFAOP Register and With a Hodgkin Lymphoma","GFAOPLH2019","Inclusion Criteria:\n\nunder 18 years of age at diagnosis\n\n* suffering from \"classical\" Hodgkin's disease according to the WHO classification.\n* with no history of hematological malignancies or constitutional or acquired immune deficiencies\n\nExclusion Criteria:\n\n* Over 18 years of age at diagnosis\n* A history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies","ALL","0 Months","18 Years",{"count":21,"type":22},250,"ESTIMATED","OBSERVATIONAL","The GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.\n\nDevelop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.",[26,27],"Staging","Therapeutic Recommendations","RECRUITING","2026-02-27",{"date":31,"type":32},"2026-03-02","ACTUAL",{"date":34,"type":32},"2022-11-15",{"date":36,"type":22},"2030-12-31",{"name":38,"class":39},"French Africa Pediatric Oncology Group","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100600523","phase-2-pancreatic-cancer-diagnosis-with-fapi-pet-imaging-100600523","NCT07098598","Pancreatic Cancer Diagnosis With FAPI-PET Imaging","Diagnostic Efficacy of 18F-FAPI-74 PET\u002FCT in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Suspected primary or recurrent pancreatic cancer\n* Subjects must be male or female aged 18-85 years.\n* WHO performance score 0-2.\n* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n* Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.\n* Study subject is not able to understand the purpose of the study.\n* Medical conditions prohibiting whole-body PET\u002FCT imaging.","85 Years",{"count":50,"type":22},100,"INTERVENTIONAL",[53,54],"PHASE2","PHASE3","Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET\u002FCT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and distant metastasis but poor in detecting local lymph node metastasis. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targets FAP, a protein overexpressed in cancer-associated fibroblasts. It presents a potential new PET imagining tool.\n\nThe objective of this prospective diagnostic study is to evaluate the diagnostic efficacy of 18F-FAPI-74 PET\u002FCT in patients with PC. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with PC in primary staging and when suspected recurrence. 100 patients with PC are enrolled on whom PET\u002FCT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.",[57,58,59,60,61,62,63,26],"Positron Emission Tomography","Pancreatic Cancer","FAPI","Diagnostics","Recurrent Pancreatic Cancer","Oncologic Surgery","Imaging, Diagnostic","2025-07-31",{"date":66,"type":32},"2025-08-01",{"date":68,"type":32},"2024-10-09",{"date":70,"type":22},"2026-10",{"name":72,"class":73},"Turku University Hospital","OTHER_GOV",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":40},"100596869","bladder-cancer-staging-and-prediction-of-new-adjuvant-chemotherapy-efficacy-based-on-deep-learning-and-transfer-learning-in-ultrasound-magnetic-resonance-pathology-multimodal-multiscale-100596869","NCT07051083","Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale","Intelligent Diagnosis of Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale","MICS-BC","Inclusion Criteria:\n\n1. Ultrasound and other imaging examinations (CT, MR, etc.) suggest bladder masses and are suspicious for bladder cancer patients.\n2. The bladder is well filled, and no allergic reactions to ultrasound contrast agents are found.\n3. No surgery or radiotherapy\u002Fchemotherapy has been performed.\n4. Patients who meet the indications for surgical resection and are planned for surgical treatment, including one of the following:\n\n   1. Clinical symptoms consistent with suspected bladder cancer (such as gross hematuria, etc.);\n   2. Patients with confirmed primary or recurrent bladder cancer by cystoscopic biopsy;\n   3. Rapid urine cytology and urine cytology FISH testing suggest malignancy.\n\nExclusion Criteria:\n\n1. Individuals unable to tolerate surgery;\n2. Individuals allergic to ultrasound contrast agents, unable to undergo ultrasound contrast examination;\n3. Unsuccessful preoperative ultrasound contrast examination or non-compliant patients;\n4. Postoperative pathology does not indicate bladder cancer;\n5. Patients who have undergone chemotherapy or radiation therapy.",{"count":83,"type":22},480,"5 Years","Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor. The involvement of muscle invasion affects the choice of surgical methods and treatment. Preoperatively, the precise assessment of bladder cancer staging has important practical value. A more accurate preoperative assessment of bladder cancer staging can reduce overtreatment and provide a favorable basis for clinicians to choose more reasonable and effective surgical methods. Clinically, there has been a longstanding desire to diagnose the staging of bladder cancer through a simple, convenient, effective, and non-invasive examination. As relevant research progresses, a multi-omics diagnostic model will be beneficial in improving diagnostic efficiency. This project aims to establish a multi-omics artificial intelligence system based on deep learning and transfer learning to accurately diagnose the staging of bladder cancer and predict the efficacy of neoadjuvant chemotherapy. This system will assist in clinical treatment decision-making.",[87,26,88,89,90],"Bladder Cancer","Deep Learning","Neoadjuvant Chemotherapy","Contrast Enhanced Ultrasound",[87,92,26,88,89,90],"Multi-omics","2025-06-26",{"date":95,"type":32},"2025-07-03",{"date":97,"type":32},"2024-01-01",{"date":99,"type":22},"2026-12-31",{"name":101,"class":39},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":110,"enrollmentInfo":111,"targetDuration":112,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":40},"100575722","ultrasound-contrast-enhanced-accurate-diagnosis-of-preoperative-staging-of-bladder-cancer-100575722","NCT06775977","Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer","Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer: a Prospective, Observational Study","UCEADP-BCS","Inclusion Criteria:\n\n* (a) eligible patients should be 18-year-old or older;\n* (b) patients should have a histologically or cytologically confirmed diagnosis of primary bladder cancer;\n* (c) patients should not have had any surgery, chemotherapy, immunotherapy, or any therapy before CEUS diagnosis.\n\nExclusion Criteria:\n\n* (a) participants with confirmed to have no carcinoma of the bladder;\n* (b) participants with previous pelvic surgery, who had undergone therapy, any bladder surgery, or had received chemotherapy, radiotherapy or immunotherapy;\n* (c) participants diagnosed with tumor recurrence or metastasis; (d) participants who were allergic to ultrasound contrast agents or could not tolerate CEUS examination, for instance, with recent myocardial infarction, angina pectoris, cardiac insufficiency, severe cardiac arrhythmia, a right\u002Fleft cardiac shunt, severe pulmonary hypertension, uncontrolled systemic hypertension, acute respiratory distress syndrome, or chronic obstructive pulmonary disease.","75 Years",{"count":83,"type":22},"6 Months","Ultrasound and magnetic resonance imaging (MRI) technologies have become essential tools for the diagnosis and preoperative staging assessment of bladder cancer. However, establishing a precise system suitable for clinical application remains a significant challenge, and accurate prediction of bladder cancer staging is not yet possible. Therefore, exploring a system for the precise diagnosis of preoperative staging of bladder cancer using ultrasound contrast enhancement or a combination of ultrasound contrast enhancement and MRI is of great importance. The applicant has previously demonstrated the accuracy of multimodal data analysis in the diagnosis and prediction of malignant tumors. Preliminary results from this study have shown that ultrasound contrast enhancement has a high diagnostic efficacy for the preoperative staging assessment of bladder cancer, with a high area under the curve (AUC) of 0.88, sensitivity of 83.3%, specificity of 92.5%, and accuracy of 90.8%. In this project, the applicant intends to further expand the sample size and, based on the combination of ultrasound contrast enhancement and MRI, develop a precise diagnostic system for the preoperative staging of bladder cancer to aid clinical treatment decisions.",[87,26,90],[87,116],"Contrast-Enhanced Ultrasonography","2025-01-21",{"date":119,"type":32},"2025-01-24",{"date":97,"type":32},{"date":122,"type":22},"2025-12-31",{"name":101,"class":39}]